Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463088 | 0.90 | ALDH1A1 (0.65) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL6825821 | 0.83 | ALDH1A1 (0.64) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL23106681 | 0.81 | CA2 (0.57) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL15948905 | 0.81 | CA2 (0.57) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL27487582 | 0.81 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL7584620 | 0.81 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8474920 | 0.80 | ALDH1A1 (0.60) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL4325357 | 0.79 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL19661520 | 0.79 | CA12 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL11763255 | 0.79 | G6PD (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851126-A1 | MAYTANSINOID-CELL-BINDING AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3524611-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3524611-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3031810-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-1651162-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8841425-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8435528-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7851432-B2 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7473796-B2 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | IMMUNOGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276497-B2 | For therapy of tumors | IMMUNOGEN INC. | 2007-10-02 | — | — | US | disclosed |
| EP-1651162-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | Immunogen, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2004103272-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264266-A1 | Maytansine derivatives having a sterically hindered thiol or disulfide groups, capable of conjugating to cell-binding agents, to form drugs having improved therapeutic efficacy in animal tumor models; antitumor agents | SPR, SDAD1, ARRB1 | ALDH1A1 506/4885CYP3A4 2049/4885CYP2C9 1565/4885 |
| US-20070270585-A1 | Maytansinoid intermediates: N-alkyl- or aryldithioalkanoylalanines and N-alkanoyl- or aroylthioalkanoylalanines, e.g., N-methyl-N-(4-methyl-4-methyldithio-1-oxopentyl)-alanine; optical isomers and racemic mixtures; preparations from isobutylene sulfide and acetonitrile, methyl methanethiosulfonate, etc. | AASDHPPT, AADAT, SLC6A15 | ALDH1A1 492/4885CYP3A4 951/4885CYP2C9 1419/4885 |
| US-20040235840-A1 | For therapy of tumors | HCCS, SPR, PAICS | ALDH1A1 1022/4885CYP3A4 3718/4885CYP2C9 3960/4885 |
| US-20070269447-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | ALDH1A1 707/4885CYP3A4 1983/4885CYP2C9 2201/4885 |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | ALDH1A1 1496/4885CYP3A4 301/4885CYP2C9 1816/4885 |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | ALDH1A1 707/4885CYP3A4 1983/4885CYP2C9 2201/4885 |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | ALDH1A1 1496/4885CYP3A4 301/4885CYP2C9 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.